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Background: The efficacy of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization
therapy-defibrillator (CRT-D) therapy has already been established in clinical trials but their effectiveness
in several clinical settings remains undetermined. This study aimed to assess the effectiveness of ICD and
CRT-D therapies within the Brazilian National Health System (SUS).
Methods: All patients who underwent ICD or CRT-D implantation within the SUS from 2001 to 2007 were
included in the study. We compared estimated Kaplan-Meier survival curves using the Peto’s test. Prognostic
factors were selected using Cox’s models.
Results: There were included 3,295 patients in the ICD group and 681 patients in the CRT-D group. Cardiac
causes accounted for 79% of all deaths in both groups and Chagas’ heart disease accounted for 31% of
these deaths. In the CRT-D group, survival significantly decreased around the fourth year of follow-up, with
a decrease from 59.5% to 38.3% in 5.5 months. Transvenous implantation technique was used in 62% of
CRT-D patients. In-hospital case-fatality rates were higher in those undergoing surgical implantation (5.3%)
than those undergoing transvenous implantation (1.6%) (p = 0.02).
Conclusions: The results show that short-term, medium-term and long-term effectiveness of ICD therapy
appears to be similar to that evidenced in clinical trials. In the CRT-D group, in-hospital case-fatality and
30-day case-fatality were higher than those reported in other studies. Surgical epicardial implantation technique
was performed in this group at a higher frequency than that reported in the literature and was associated with poorer
short-term prognosis.
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The efficacy of implantable cardioverter-defibrillator (ICD)
therapy for primary and secondary prevention of sudden
cardiac death has been established in several clinical sce-
narios in patients with both ischemic and nonischemic
heart disease [1]. The efficacy of cardiac resynchronization
therapy combined with ICD (cardiac resynchronization
therapy-defibrillator, CRT-D) in reducing overall mortality
has also been shown in some clinical settings compared
with optimal pharmacological therapy [2], ICD alone [3] or
even with the CRT-alone [4].
However, clinical trials do not assess the effectiveness
of these therapies under real life conditions of use where
patient follow-up is a common problem [5]. Other com-
mon issues include inappropriate indications, suboptimal
adherence to guidelines and off-label uses [6], more het-
erogeneous patient populations, and potential provider-
or device-related technical shortcomings. Furthermore,
evidence showing long-term effectiveness of these ther-
apies is scarce [7] and some controversial issues have
not been properly addressed in clinical trials, including
indications of dual-chamber ICD [8], use of ICD and
CRT-D in children and adolescents [9] and in patients
with Chagas’ heart disease [10].
In the light of these issues and scarcity of population-
based data on ICD implantation [11] particularly lack of
national registries—administrative databases have in-
creasingly gained importance as a source of information
complementary to data obtained from clinical trials and
specific records [12].
Therefore, probabilistic record linkage techniques have
been used in cardiology research to analyze population
data from routine hospital administrative databases and
nationwide death records [13]. These national databases
are essential sources of information in countries with great
population heterogeneity and a wide range of patterns of
therapy utilization.
The present study aimed to assess short-term, medium-
term and long-term survival of ICD and CRT-D therapies
within the Brazilian National Health System (SUS) using
record linkage between two national databases.
Methods
Study population and data sources
Two national databases were used as data sources for
the study: the Brazilian Mortality Database (known by
its Portuguese acronym SIM) and the Brazilian Hospital
Information Database (known by its Portuguese acronym
SIH). SIM was created in 1975 and covers the entire
population nationwide. Mortality data is considered reli-
able from the qualitative point of view, as accurate as that
of other countries with a long tradition in these statistics
[14]. SIH was created in 1981 and covers the entire Brazilian
National Health System (SUS), which provides universalhealth coverage for over 200 million people, with 75% of
them covered exclusively by it. The accuracy of the SIH
variables related to the diagnosis, medical procedures, sex,
age-group and in-hospital outcomes are considered satis-
factory [15].
Our study cohort consisted of all patients admitted to
SUS hospitals (either public or SUS-affiliated private)
undergoing transvenous ICD or CRT-D implantation from
2001 to 2007. The main clinical indications (Class I) for
ICD implantation within SUS during the study period
following the Brazilian Ministry of Health guidelines
included: cardiac arrest due to ventricular tachycardia or
ventricular fibrillation from irreversible causes in patients
with EF ≤35%; spontaneous sustained ventricular tachy-
cardia from irreversible causes in patients with EF ≤35%;
non-sustained ventricular tachycardia with previous
acute myocardial infarction, left ventricular dysfunc-
tion (EF ≤40%) and sustained ventricular tachycardia or
ventricular fibrillation inducible at programmed ventricu-
lar stimulation. CRT-D therapy was primarily indicated
for patients meeting one of the above criteria for ICD
implantation and QRS duration equal to or greater than
130 ms, functional class III or IV (The New York Heart
Association [NYHA] Functional Classification) and left
ventricle end-diastolic diameter equal to or greater than
55 mm and EF ≤0.30.
A probabilistic record linkage technique was used to
find death records for each patient in the national SIM
database during the study period. We chose to apply the
probabilistic record linkage as there is no unique identifier
between SIM and SIH databases. The linkage method ap-
plied showed 90.6% sensitivity and 100% specificity [16].
Data analysis
We performed an overall survival and cardiac survival
analysis considering only deaths from any underlying car-
diac cause (including Chagas’ heart disease and congenital
heart disease), procedure-related complications or other
causes potentially related to sudden cardiac death accord-
ing to the following codes: T821; I00-I528; B570-B572;
Q200-Q249; R570; R960, and R98 (International Statistical
Classification of Diseases and Related Health Problems,
10th Revision).
Patients who did not die by the end of the study period
(12/31/2007) were censored. No patient was lost to follow-
up during the study period assuming universal coverage of
SIM nationwide and no deaths occurring abroad. As for
cardiac survival rates, patients whose underlying cause
of death was not defined as of cardiac origin were also
censored and were included in the analysis on the date
of death or on the last date of observation. The start
time of observation for each individual (T0) was the
date of hospitalization for the implantation procedure.
If a patient underwent more than one ICD or CRT-D
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Generator replacement and/or lead revision procedures or
any other procedures not related to device implantation
were disregarded.
Due to differences in clinical eligibility criteria, patients
were divided into two therapy groups for the analysis: ICD
alone and CRT-D. Survival curves were estimated using
the Kaplan-Meier method and compared using Peto’s test
at a significance level of p <0.05. The variables selected
in the univariate Cox proportional hazards regression
models—adjusted for age in years—were included in
the multivariate models to estimate the independent
effect of the variables. The following variables were stud-
ied in the models in both groups: age; gender; hospital cat-
egory; year of device implantation; and hospital location
(state). We analyzed type of device (dual- or single-
chamber) in the ICD-alone group and implantation tech-
nique (transvenous or mini-thoracotomy) in the CRT-D
group. Separate models were constructed for overall and
cardiac survival analysis stratified by therapy group (ICD
alone or CRT-D). We estimated hazard ratios (HR) and
their related 95% confidence intervals. Schoenfeld resid-
uals were used to test the proportional hazards assump-
tion of Cox models.
In Brazil, hospital admissions authorization (AIH) forms
include a field for the principal diagnosis of current ad-
mission and a second one for secondary diagnosis. In the
ICD-alone group, 91.83% of admission forms included the
arrhythmia code as principal diagnosis but did not provide
any information on the underlying disease. In the CRT-D
group, a greater proportion of patient forms (33.3%) in-
cluded information on the underlying disease at admis-
sion. Since there was no information on the underlying
disease for many patients, we thus chose not to include
this variable in the Cox models. We therefore included a
new variable for underlying cardiac disease using all the
disease codes from the two AIH fields and the five SIM
fields, including the “contributing cause”, which may also
display several codes for diseases not directly associated
with the death. As a result, we were able to determine
underlying disease for another 581 patients.
In-hospital case fatality was estimated based on deaths
occurring during the admission when the first ICD or
CRT-D implantation was performed. We calculated mean
length of stay of these admissions.
For the comparison of means, we performed Student’s
t-test for variables with normal distribution or otherwise
the Mann-Whitney U-test. For the comparison of propor-
tions, we used the chi-squared test. The statistical signifi-
cance was set at p < 0.05. Data analyses were performed
using the R Statistical Package, version 2.6.2.
This study was approved by the research ethics commit-
tee (name: Comitê de Ética em Pesquisa COEP-UFMG,
protocol number 0084.0.203.000-09) and followed theprinciples of the Declaration of Helsinki. The ethics
committee waived the requirement for written informed
consent due to the study’s design.
Results
The ICD group comprised 3,295 patients from 85 hospi-
tals with a mean observation time of about 2.5 years,
maximum follow-up time of approximately 7 years and
799 deaths were observed. CRT-D therapy became avail-
able to SUS patients in 2002, and 681 patients from 50
hospitals had received the device by 2007. The mean
follow-up time in the CRT-D group was 16 months, max-
imum follow-up time was slightly over 5 years and 197
deaths were observed.
Single-chamber ICDs were more often implanted (64%)
than dual-chamber devices. Dual-chamber devices became
available to SUS patients in 2004 and accounted for 65%
of all devices implanted in the ICD-alone group during
2005–2007. In general, the variables studied were similar
in patients receiving single-chamber ICDs, dual-chamber
ICDs and CRT-D (Table 1). The mean age was lower in
the ICD-alone than CRT-D group (58 vs. 61 years, p <
0.001). The CRT-D group had a higher proportion of eld-
erly (70 years or older) (p <0.01) and lower proportion of
patients aged 10 to 49 years (p <0.001) when compared
to the ICD-alone group. A comparison of device implant
between Brazilian states showed that most procedures—
especially CRT-D—were performed in care facilities in São
Paulo, which is the richest and most industrialized state in
Brazil. We found a lower proportion of supraventricular
tachycardia among patients receiving dual-chamber com-
pared to single-chamber ICDs (p <0.001).
Among patients with information about underlying dis-
ease, in the ICD-alone group (n = 760), 36% were diag-
nosed with Chagas’ heart disease and 25.1% with ischemic
heart disease (Table 2). In the CRT-D group (n = 310),
12.3% were diagnosed with Chagas’ heart disease (Table 2).
The underlying cardiac diseases by age groups were de-
scribed in Table 3. Cardiac causes accounted for 79% of
deaths in both groups (Table 4), and Chagas’ heart disease
accounted for 33% and 23% of cardiac deaths in the ICD-
alone and CRT-D groups, respectively (p < 0.05). Of all
deaths, there were only six unattended deaths in the ICD-
alone group and one in the CRT-D group.
The mean length of hospital stay for device implant-
ation was shorter in ICD-alone compared to CRT-D pa-
tients (5.8 vs. 7.7 days, p <0.001). The in-hospital case
fatality was 0.3% in the ICD group and 2.9% in the CRT-D
group (p <0.001). The in-hospital case fatality of CRT-D
patients over 70 was 8.5%. Overall short-term, medium-
term and long-term survival and short-, medium- and
long-term cardiac survival (30 days, 1 year and 5 years, re-
spectively) are presented in Figures 1 and 2, stratified by
type of therapy. The differences found in survival times of
Table 1 Baseline patient characteristics stratified by type of ICD
Type of ICD
Characteristics Single-chamber ICD Dual-chamber ICD CRT-D
(n = 2,109) (n = 1,186) (n = 681)
Age (years), mean (SD) 56 (±14) 57 (±14) 60 (±12)
Age group, n (%)
<10 years 6 (0.3) 3 (0.3) 2 (0.3)
10 to 49 years 580 (27.5) 321 (27.1) 127 (18.7)
50 to 59 years 580 (27.5) 310 (26.1) 189 (27.8)
60 to 69 years 587 (27.8) 362 (30.5) 219 (32.2)
70 years or more 356 (16.9) 190 (16.0) 143 (21.0)
Sex, n (%)
Female 626 (29.7) 365 (30.8) 176 (25.8)
Male 1482 (70.3) 821 (69.2) 505 (74.2)
Arrhythmia, n (%)
Ventricular Flutter or Fibrillation 407 (19.3) 356 (30.0) 13 (1.9)
Ventricular Tachycardia 914 (43.3) 618 (52.1) 242 (35.5)
Supraventricular Tachycardia 514 (24.4) 101 (8.5) 2 (0.3)
Hospital location (state), n (%)
São Paulo 1069 (50.7) 703 (59.3) 486 (71.4)
Other 1040 (49.3) 483 (40.7) 195 (28.6)
Category of hospital, n (%)
Charity Hospital 814 (38.6) 587 (49.5) 377 (55.4)
Private Hospital (non-philanthropic) 245 (11.6) 175 (14.8) 38 (5.6)
Public Hospital 1050 (49.8) 424 (35.8) 266 (39.1)
Implant technique – mini-thoracotomy, n (%) 0 0 227 (38.0)
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for all periods studied, for both overall and cardiac sur-
vival (Figures 1 and 2). Patients in the CRT-D group
showed poorer prognosis (Figure 1). A marked drop in
survival was evident in the CRT-D group around the
fourth year of observation (Figure 1), with a decrease in
survival rates from 59.5% (95% CI 54.3–65.3) to 38.3%
(95% CI 27.7–52.9) in only 5.5 months.
The analysis of overall survival of ICD patients showed
that age was associated with the outcome (HR 1.03, 95%Table 2 Underlying cardiac disease by type of ICD
Underlying cardiac disease, n (%) Type of ICD
ICD CRT-D
Cardiomyopathy 172 (22.6) 202 (65.2)
Chagas’ heart disease 274 (36.1) 38 (12.3)
Congenital heart disease 45 (5.9) 0 (0.0)
Ischemic heart disease 191 (25.1) 61 (19.7)
Other causes (myocarditis, valvular heart
disease, hypertensive heart disease)
78 (10.26) 9 (2.9)
Total 760 (100) 310 (100)CI 1.03–1.04), with 3% increase in the risk of death
per year. This association remained in the multivari-
ate models for both overall and cardiac survival. There
were no deaths in children in our study. In the ICD group,
the 1-year survival was 93.8% (95% CI 92.2–95.5) in pa-
tients aged 10 to 49 years and 81.6% (95% CI 78.3–85.1)
in those 70 years or more. No other variables studied were
significantly associated with the outcome in either group.
Figure 3 shows survival curves with underlying disease
information drawn from the AIH for the ICD-alone
group. This Figure does not include the information on
underlying disease drawn from the mortality database,
because – as we used specific data on patients who
died – survival would be artificially low. Kaplan-Meier
survival estimates were not significantly different (Peto’s
test, p = 0.84) between the two groups (with and with-
out underlying disease at SIH), suggesting random loss
of these information. The cardiac survival curves were
very similar to these overall survival curves, showing the
same pattern.
In the CRT-D group, it was used a transvenous endo-
cardial technique in 62% patients, epicardial in 28% and
Table 3 Underlying cardiac disease by age group
Underlying cardiac disease, n (%) Age group, n (%)
<10 years 10 to 19 20 to 29 30 to 39 40 to 49 50 to 59 60 to 69 70 years or more
Cardiomyopathy 1 (100) 6 (42.9) 12 (44.4) 22 (44.0) 50 (42.0) 93 (32.4) 111 (33.0) 78 (33.2)
Chagas’ heart disease 0 (0.0) 0 (0.0) 4 (14.8) 18 (36.0) 44 (37.0) 96 (33.4) 100 (29.8) 50 (21.3)
Congenital heart disease 0 (0.0) 4 (28.6) 4 (14.8) 0 (0.0) 8 (6.7) 6 (2.1) 13 (3.9) 10 (4.3)
Ischemic heart disease 0 (0.0) 2 (14.3) 4 (14.8) 6 (12.0) 10 (8.4) 65 (22.6) 89 (26.5) 76 (32.3)
Other causes (myocarditis, valvular heart
disease, hypertensive heart disease)
0 (0.0) 2 (14.3) 3 (11.1) 4 (8.0) 7 (5.9) 27 (9.4) 23 (6.8) 21 (8.9)
Total 1 (100) 14 (100) 27 (100) 50 (100) 119 (100) 287 (100) 336 (100) 235 (100)
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ure in 10%. The in-hospital case fatality was 5.3% among
those undergoing epicardial lead placement, which is
higher than 1.6% found among those undergoing transve-
nous implantation (p <0.05) considering that both groups
had a similar median length of hospital stay (4 days).
Those requiring thoracotomy due to implant failure
accounted for 25.1% of all patients undergoing epicar-
dial technique and 16.7% of deaths in this group. There
were no significant differences in the medium-term and
long-term prognosis according to implantation technique
(Figure 4).
Discussion
To the best of our knowledge, this is the first study to
analyze survival in all patients undergoing ICD and
CRT-D implantation within a National Health System.
This design allowed to avoiding selection bias and in-
creasing the generalizability of effectiveness results.
Overall 1-year, 2-year and 3-year survival rates in the
ICD-alone group were similar to those reported in the
AVID study (89.3%, 81.6% and 75.4%, respectively) [17].
In addition, the rate of cardiac deaths was similar to that
reported in the same study [18]. One-year, 2-year, 3-year,









(n = 2,109) (n = 1,186) (n = 681)
Chagas’ heart disease 167 (26.0%) 42 (26.8%) 36 (18.3%)
Cardiac diseases (other) 340 (53.0%) 82 (52.2%) 119 (60.4%)
Noncardiac vascular
diseases
17 (2.6%) 5 (3.2%) 8 (4.1%)
Cancer 16 (2.5%) 2 (1.3%) 4 (2.0%)
Infection 12 (1.9%) 2 (1.3%) 0 (0.0%)
Other 90 (14.0%) 24 (15.3%) 30 (15.2%)
Total 642 (100%) 157 (100%) 197 (100%)groups were similar to those described in a large case series
in the US [7]. The overall 5-year survival in our study was
similar to that reported in the RAFT Trial (65.4%) among
ICD patients, but considerably lower than that reported in
CRT-D patients [19]. This difference in long-term progno-
sis may be explained by the inclusion of patients with
NYHA functional class II or III in this study. The one-
year survival in the CRT-D group was lower than the 88%
described in the COMPANION trial, even when the group
undergoing transvenous implant was considered individu-
ally [2].
The 5-year survival found among ICD patients in our
study was very similar to that observed in a study of pa-
tients with Chagas’ heart disease [10]. Although Chagas
disease was the underlying cause in one-third of all patients
who eventually died, we cannot infer that these patients
had a poorer prognosis. Our survival curves by underlying
disease suggests that etiology of heart disease (Chagas vs.
ischemic heart disease) was not a prognostic factor. The
ICD-LABOR study that also included patients with Chagas’
heart disease found similar results [20]. Barbosa et al. sug-
gested that Chagas’ heart disease patients are more likely to
have ventricular arrhythmias than patients with other cardi-
opathies, but on the other hand, they have higher rates of
appropriate ICD therapy [21].
The in-hospital case fatality of 0.33% observed in the
ICD group in our study was only slightly higher than the
0.2% reported in a systematic review of nonthoracotomy
ICD trials [22] but considerably lower than that reported
in other clinical data analyses [12,23,24]. Nevertheless, the
1.1% 30-day case fatality observed was identical to that re-
ported in the AVID trial, but higher than the 0.6% found
in a systematic review of nonthoracotomy ICD trials by
Rees et al. [22]. The mean length of hospital stay among
ICD patients was shorter than that reported in a large
study of administrative databases in the US [12].
The in-hospital case fatality of 2.9% seen in the CRT-D
group was higher than the 0.5% case fatality reported in
a systematic review [25], 0.9% reported by Swindle et al.
[23] and 1.1% reported in Medicare patients [24]. The
COMPANION and MADIT-CRT trials also found much
Figure 1 Overall survival by therapy (ICD-alone or CRT-D). Kaplan-Meier survival estimates were significantly different between the two
groups (95% CI).
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than that found in the present study; however, both stud-
ies excluded patients with implantation with thoracotomy
and the MADIT-CRT trial included only patients with
NYHA Class I and II [22]. Even the in-hospital case fa-
tality in the CRT-D sub-group undergoing transvenous
implantation (1.6%) was higher than those reported in
these studies. The 8.5% in-hospital case fatality in CRT-D
patients older than 70 was much higher than that reported
by Swindle et al. in elderly patients [23]. The 30-day mortal-
ity in those undergoing transvenous CRT-D implantation
in our study (4.1%) was higher than the 1.8% observed in
the COMPANION trial [2]. Even among younger patients,
the mean length of stay in the CRT-D group was higher
within SUS than that reported in Zhan et al. study [12].
The median length of hospital stay in our study was the
same regardless of the implant technique.
Our study did not find any deaths in children under-
going ICD implantation. Other study corroborate the
good prognosis in this age group [9]. Differences in sur-
vival times between ICD-alone or CRT-D patients were
expected because the indication criteria for CRT-Dimplant included poor functional status (NYHA Class III
or IV) and ventricular dyssynchrony.
The decrease in survival among CRT-D patients around
the fourth year of follow-up may suggest the impact of the
disease natural history or device-related problems. A study
by Cleland and colleagues with patients with heart failure
and dyssynchrony found among those treated with med-
ical therapy alone a pattern of decline in survival mainly
due to sudden death that is similar to that observed in our
study [26]. However, this pattern of survival was not ob-
served in Saxon and colleagues study that also assessed
long-term outcomes [7]. One explanation for this pattern
would be the effect of a factor affecting the long-term ef-
fectiveness of CRT-D therapy and its impact in the disease
natural history. Horlbeck and colleagues showed that
mean lifetime of CRT-D devices was 4 years [27]. Like-
wise, Biffi and colleagues demonstrated that median life-
time of CRT-D devices was approximately 4 years [28].
Thijssen and colleagues reported that mean battery life-
time of CRT-D devices was 4.7 years [29]. In an earlier
study by Hauser and colleagues (1998–2005) only 4% of
CRT-D pulse generators were operating normally within
Figure 2 Cardiac survival by therapy (ICD-alone or CRT-D). Kaplan-Meier survival estimates were significantly different between the two
groups (95% CI).


























ischemic heart disease (n=63)
cardiomyopathy (n=51)
Chagas' heart disease (n=43)
congenital heart disease (n=45)
other causes (n=60)
Figure 3 Overall survival by underlying cardiac disease
(ICD-alone group). Kaplan-Meier survival estimates were not
significantly different between groups (Peto’s test p = 0.05).
These survival curves with underlying disease information drawn
only from the hospital admission (AIH) forms.
Figure 4 Overall survival by implant technique. Kaplan-Meier
survival estimates were not significantly different between the two
groups (Peto’s test p = 0.263). The group we denominated ‘thoracotomy’
comprises two subgroups with survival curves overlaid: patients with
surgically-implanted left ventricle leads as the first approach and
patients with transvenous implantation failure, who were subsequently
converted to thoracotomy.
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and colleagues reported that at three years slightly more
than 10% of patients underwent surgical revision for bat-
tery depletion and at four years this rate rose to about 50%
[31]. This same study showed that patients undergoing re-
placement had double the risk of infection, which could
also explain the mortality observed in our study. Only on-
going monitoring can establish whether this finding was
exclusive to the initial cohort of patients undergoing CRT-
D implantation (long follow-up) and to what extent it was
impacted by the small number of patients at-risk in the
fourth year of follow-up.
Dual-chamber devices accounted for 65% of all ICD
implants In the last three years studied, a percentage
that is similar to that reported in the US National ICD
Registry (62% from 2006 to 2007) [8]. In this study only
40.4% of patients implanted with dual-chamber ICD de-
vices met the indications for pacemaker therapy and the
use of dual-chamber ICD devices was associated with in-
creased in-hospital complications and in-hospital case
fatality rates [8]. In our study we found no differences in
in-hospital case fatality and short-term, medium-term
and long-term survival rates among those implanted
with single- and dual-chamber devices. Those undergo-
ing dual-chamber ICD implantation were less likely to
have supraventricular tachycardia, which contrasts with
that reported by Dewland and colleagues [8], suggesting
that this is not a common indication for atrial lead place-
ment in Brazilian patients.
The present study showed that the proportion of CRT-D
with surgically implanted left ventricle leads as first ap-
proach (28%) seems slightly greater than that reported in
other studies (24.1% to 24.9%) [32,33]. The percentage of
transvenous implantation failure in our study (13.7%) was
also higher than that reported in other studies with CRT-D
(5.9% to 11%) [32-34]. In patients undergoing CRT-D im-
plantation, epicardial lead placement was found associated
with increased in-hospital case fatality, as suggested in
other studies with CRT [35] and CRT-D [32]. Despite in-
creased in-hospital case fatality and 30-day case-fatality, we
found similar medium-term and long-term survival rates
for both implantation techniques suggesting similar effect-
iveness of these techniques in patients surviving the initial
post-implantation period, which corroborates that reported
by Miller and colleagues [35] with CRT. However, conflict-
ing results have been reported. One study showed poorer
short-term and long-term prognosis with the epicardial
technique [32] while other studies found no significant dif-
ferences in short-term or long-term results [33,36]. The re-
sults found in our study regarding the epicardial technique
may be explained by the “learning curve” of surgical teams,
quality of postoperative care and potentially suboptimal
drug therapy prescribed to patients with advanced heart
failure referred to surgery [37].Our study has some limitations common to studies
relying on administrative databases. The lack of informa-
tion on patient variables such as NYHA functional class,
left ventricle ejection fraction, and history of sudden car-
diac death does not allow proper adjustment for the pa-
tients’ baseline risk. The proportion of underlying diseases
may not reflect their actual distribution in the study popu-
lation due to missing information on this variable in SIH
database. Information on the underlying condition is often
missing in hospital admission authorization forms because
providers are required to fill out two different diagnosis
fields including diagnostic codes to support the patient’s
eligibility for device implantation (e.g., type of arrhythmia
and heart failure). The sensitivity of the probabilistic rec-
ord linkage method used to find deaths registries (90.6%)
may have potentially missed some death records in the
database. However, there was 100% specificity in identify-
ing deaths records and probably random loss [16].
Conclusion
Our study showed that the medium-term and long-term
effectiveness of ICD therapy in Brazil appears to be simi-
lar to the efficacy found in clinical trials. However, there
is an apparent slight excess of deaths within the first
30 days of implantation. Younger age at the time of im-
plantation was a predictor of better prognosis in the
ICD-alone group. In the CRT-D group, in-hospital case
fatality and 30-day case fatality were higher than those
reported in other studies. There was a marked drop in
survival around the fourth year after implantation, and
further investigation is necessary to determine its causes.
In addition, the epicardial implantation technique was
more frequently used in the CRT-D group than that re-
ported in the literature and was found to be associated
with poorer short-term prognosis. The study results sug-
gest there is still room for reducing the proportion of
surgical procedures within SUS, and more importantly,
actions should be taken to reduce mortality associated
with surgical CRT-D implantation and transvenous im-
plantation of both ICDs and CRT-Ds.
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